Phreesia, Inc. (NYSE:PHR) Position Decreased by Riverbridge Partners LLC

Riverbridge Partners LLC trimmed its holdings in shares of Phreesia, Inc. (NYSE:PHR - Free Report) by 9.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 683,888 shares of the company's stock after selling 69,341 shares during the period. Riverbridge Partners LLC owned about 1.18% of Phreesia worth $17,207,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Trust Point Inc. lifted its position in Phreesia by 3.5% during the third quarter. Trust Point Inc. now owns 17,887 shares of the company's stock valued at $408,000 after buying an additional 607 shares in the last quarter. Ensign Peak Advisors Inc lifted its position in Phreesia by 3.2% during the second quarter. Ensign Peak Advisors Inc now owns 22,491 shares of the company's stock valued at $477,000 after buying an additional 700 shares in the last quarter. The Manufacturers Life Insurance Company lifted its position in Phreesia by 3.3% during the third quarter. The Manufacturers Life Insurance Company now owns 27,935 shares of the company's stock valued at $637,000 after buying an additional 905 shares in the last quarter. MetLife Investment Management LLC lifted its position in Phreesia by 3.8% during the third quarter. MetLife Investment Management LLC now owns 30,781 shares of the company's stock valued at $701,000 after buying an additional 1,120 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Phreesia by 9.9% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,015 shares of the company's stock valued at $319,000 after buying an additional 1,258 shares in the last quarter. 92.10% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Phreesia

In other news, CFO Balaji Gandhi sold 5,827 shares of the firm's stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $27.31, for a total transaction of $159,135.37. Following the completion of the transaction, the chief financial officer now owns 141,846 shares in the company, valued at approximately $3,873,814.26. This trade represents a 3.95 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, SVP Amy Beth Vanduyn sold 25,447 shares of the firm's stock in a transaction dated Tuesday, December 3rd. The shares were sold at an average price of $20.93, for a total transaction of $532,605.71. Following the transaction, the senior vice president now owns 93,470 shares of the company's stock, valued at approximately $1,956,327.10. This trade represents a 21.40 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 131,756 shares of company stock worth $3,244,909 in the last 90 days. Corporate insiders own 5.80% of the company's stock.

Phreesia Stock Performance

Shares of PHR stock traded up $0.02 during trading hours on Thursday, reaching $27.24. The stock had a trading volume of 160,269 shares, compared to its average volume of 368,961. The company has a debt-to-equity ratio of 0.04, a current ratio of 1.74 and a quick ratio of 1.74. Phreesia, Inc. has a twelve month low of $17.07 and a twelve month high of $29.16. The firm has a 50-day simple moving average of $23.87 and a 200-day simple moving average of $22.97. The firm has a market capitalization of $1.58 billion, a PE ratio of -18.48 and a beta of 0.94.

Phreesia (NYSE:PHR - Get Free Report) last released its quarterly earnings data on Monday, December 9th. The company reported ($0.25) earnings per share for the quarter, topping analysts' consensus estimates of ($0.29) by $0.04. Phreesia had a negative net margin of 20.43% and a negative return on equity of 32.78%. The business had revenue of $106.80 million for the quarter, compared to analysts' expectations of $106.33 million. During the same quarter last year, the company earned ($0.58) EPS. The company's revenue for the quarter was up 16.6% compared to the same quarter last year. As a group, equities analysts forecast that Phreesia, Inc. will post -1.1 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on PHR shares. Robert W. Baird reduced their price target on shares of Phreesia from $34.00 to $30.00 and set an "outperform" rating on the stock in a research report on Wednesday, December 11th. Royal Bank of Canada upgraded shares of Phreesia from a "sector perform" rating to an "outperform" rating and upped their target price for the company from $24.00 to $32.00 in a research note on Wednesday, January 8th. Citigroup upped their target price on shares of Phreesia from $31.00 to $35.00 and gave the company a "buy" rating in a research note on Friday, January 10th. KeyCorp upped their target price on shares of Phreesia from $28.00 to $30.00 and gave the company an "overweight" rating in a research note on Wednesday, January 8th. Finally, Truist Financial upped their target price on shares of Phreesia from $31.00 to $34.00 and gave the company a "buy" rating in a research note on Wednesday, December 11th. Twelve equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company has an average rating of "Buy" and an average target price of $31.00.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.